Engaging in Groundbreaking Research, Volition Advances Health
Volition Takes Center Stage at ISICEM
VolitionRx Limited (NYSE AMERICAN: VNRX) is excited to announce its notable participation at the prestigious International Symposium on Intensive Care & Emergency Medicine (ISICEM) Congress, which is a significant event drawing healthcare professionals and researchers in critical care from around the globe. As one of the silver sponsors, Volition will host a series of presentations emphasizing their innovative Nu.Q® H3.1 epigenetic screening technology, specifically tailored for intensive care and emergency medicine.
Importance of Nu.Q® H3.1 Technology
Dr. Andrew Retter, Volition's Chief Medical Officer, expressed enthusiasm about the company’s involvement at ISICEM, highlighting groundbreaking studies aimed at improving the screening, monitoring, and early intervention of sepsis in intensive care unit settings. These presentations underscore the growing recognition of NETosis and nucleosomes-H3.1's role in enhancing patient outcomes, opening up potential market opportunities exceeding $1 billion in managing sepsis alone.
Diverse Presentations Scheduled
Presentations featuring the Nu.Q® H3.1 technology will cover various critical topics vital for healthcare professionals:
- Presentation 1: Circulating NETs levels
Date and Time: Tuesday, March 18, 2025, at 2:30 PM
Speaker: Professor Djillali Annane
Location: Panoramic Room - Presentation 2: Functional endotyping in sepsis
Date and Time: Wednesday, March 19, 2025, at 9:45 AM
Speaker: Professor Evangelos Giamarellos-Bourboulis
Location: 100 Hall - Presentation 3: Neutrophils in host response and organ dysfunction
Date and Time: Wednesday, March 19, 2025, at 1:45 PM
Speaker: Professor Michael Bauer
Location: Arc Room - Presentation 4: The Time for Precision has Come
Date and Time: Wednesday, March 19, 2025, at 3:35 PM
Speaker: Professor Evangelos Giamarellos-Bourboulis
Location: Arc Room - Presentation 5: H3.1 for early recognition of sepsis
Date and Time: Thursday, March 20, 2025, at 10:00 AM
Speaker: Professor Djillali Annane
Location: 100 Hall - Presentation 6: NETosis an important predictor of organ dysfunction
Date and Time: Thursday, March 20, 2025, at 11:00 AM
Speaker: Dr. Lieuwe Bos
Location: 100 Hall
Expanding Research and Training Initiatives
In addition to presentations, Dr. Retter will also participate in the Praetorian Doctoral Network Satellite Symposium at ISICEM. This engaging session is centered on using the Nu.Q® test to measure levels of circulating H3.1 nucleosomes, which serves as a surrogate marker for neutrophil extracellular traps (NETs) in blood.
The Praetorian Network is designed to train a group of doctoral candidates who will collaboratively develop novel approaches in precision sepsis patient care. This initiative aims to address urgent clinical needs by creating advanced diagnostics and therapeutic solutions.
The Significance of ISICEM
The ISICEM Congress stands out as one of the premier events in the field of intensive care, gathering thousands of professionals keen on improving their clinical management skills. The congress acts as a platform for exchanging knowledge, showcasing the latest research, and fostering training opportunities that directly impact patient care and outcomes.
About Volition and Its Mission
Volition is dedicated to enhancing the science of epigenetics and plays a vital role in early disease detection. With a focus on advancing technology, Volition aims to improve outcomes for human and animal health. Through the development and commercialization of simple yet effective blood tests, the company is tackling life-altering diseases, including various cancers and conditions related to NETosis such as sepsis.
Headquartered in Belgium, Volition has additional offices in the United States and London, supporting global operations. Its commitment to research fosters innovation and continuous improvement within the diagnostic sector, granting better chances for early diagnosis and treatment monitoring.
Frequently Asked Questions
What is the ISICEM Congress?
The ISICEM Congress is a major international event focused on intensive care and emergency medicine, bringing together professionals from around the world.
What technology will Volition showcase at ISICEM?
Volition will showcase its Nu.Q® H3.1 epigenetic screening technology targeted for use in critical care settings.
When is Volition presenting at the congress?
Volition has several presentations scheduled from March 18 to March 20, 2025, covering various aspects of critical care medicine.
Who is Dr. Andrew Retter?
Dr. Andrew Retter is the Chief Medical Officer at Volition and will be presenting at the ISICEM Congress.
What is the objective of the Praetorian Network?
The Praetorian Network aims to develop new approaches in precision sepsis care through training doctoral candidates to address clinical needs.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
